MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

Home・Akciju saraksts・Microbot Medical Inc

Microbot Medical Inc

Slēgts

2.4 0.84

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

2.38

Max

2.4

Galvenie mērījumi
By Trading Economics
Ienākumi	113K -3.5M
Darbinieki	20
EBITDA	-561K -4.1M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+212.5% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 12. maijs

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-15M 154M
Iepriekšējā atvēršanas cena	1.56
Iepriekšējā slēgšanas cena	2.4

Tehniskais rādītājs

By Trading Central

Pārliecība

Neutral Evidence

2.52 / 2.57 Atbalsts un pretestība

Microbot Medical Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 3. apr. 04:27 UTC

Galvenie ziņu notikumi

Singapore PM Warns That Fallout From Mideast War Could Outlast Conflict

2026. g. 3. apr. 20:50 UTC

Tirgus saruna

Tech, Media & Telecom Roundup: Market Talk

2026. g. 3. apr. 18:30 UTC

Galvenie ziņu notikumi

An F15-E Just Went Down in Iran. What to Know About the $30 Million Jet. -- Barrons.com

2026. g. 3. apr. 18:14 UTC

Tirgus saruna

Eli Lilly Seen as Possible GLP-1 Leader With New Pill Approval -- Market Talk

2026. g. 3. apr. 17:50 UTC

Tirgus saruna

Microsoft's AI Development Will Weigh on Near-Term Azure Growth -- Market Talk

2026. g. 3. apr. 17:44 UTC

Iegādes, apvienošanās, pārņemšana

SBA Stock Just Had a Big Day. Why It's Suddenly Hot. -- Barrons.com

2026. g. 3. apr. 16:50 UTC

Galvenie ziņu notikumi

An F15-E Just Went Down in Iran. What to Know About the $90 Million Jet. -- Barrons.com

2026. g. 3. apr. 16:20 UTC

Tirgus saruna

Tech, Media & Telecom Roundup: Market Talk

2026. g. 3. apr. 16:12 UTC

Peļņas

Oil Stocks Look Tapped Out. Why It's Time to Move Into Other Sectors. -- Barrons.com

2026. g. 3. apr. 15:56 UTC

Tirgus saruna

Galvenie ziņu notikumi

Crypto Markets May Be Active Over Holiday Weekend -- Market Talk

2026. g. 3. apr. 15:56 UTC

Tirgus saruna

Galvenie ziņu notikumi

Global Equities Roundup: Market Talk

2026. g. 3. apr. 15:56 UTC

Tirgus saruna

Galvenie ziņu notikumi

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 3. apr. 15:20 UTC

Galvenie ziņu notikumi

Berkshire, Travelers Join U.S. Plan to Insure Shippers in the Hormuz Strait -- Barrons.com

2026. g. 3. apr. 15:08 UTC

Iegādes, apvienošanās, pārņemšana

OpenAI Makes Surprise Media Acquisition Ahead of IPO. Why It Will Fail. -- Barrons.com

2026. g. 3. apr. 14:11 UTC

Tirgus saruna

Galvenie ziņu notikumi

Oil Shock From War in Iran May Show Up In 2Q Job Growth Data -- Market Talk

2026. g. 3. apr. 12:56 UTC

Tirgus saruna

Treasury Yields, Dollar Higher Following Robust March Hiring -- Market Talk

2026. g. 3. apr. 08:20 UTC

Tirgus saruna

Tech, Media & Telecom Roundup: Market Talk

2026. g. 3. apr. 08:01 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 3. apr. 08:01 UTC

Tirgus saruna

Meituan's Profitability Likely to Improve This Year -- Market Talk

2026. g. 3. apr. 07:45 UTC

Tirgus saruna

LG Electronics Could Post Above-Consensus 1Q Earnings -- Market Talk

2026. g. 3. apr. 06:17 UTC

Tirgus saruna

Naver Likely to Post Below-Consensus 1Q Earnings -- Market Talk

2026. g. 3. apr. 06:17 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 3. apr. 04:33 UTC

Tirgus saruna

China Merchants Port Earnings Likely to Recover This Year -- Market Talk

2026. g. 3. apr. 04:33 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 3. apr. 04:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2026. g. 3. apr. 04:01 UTC

Tirgus saruna

Posco Holdings 1Q Earnings Could Fall Short of Expectations -- Market Talk

2026. g. 3. apr. 02:01 UTC

Tirgus saruna

India Consumer-Staple Companies Likely to Post Broadly Steady 4Q Results -- Market Talk

2026. g. 3. apr. 01:59 UTC

Tirgus saruna

Sea's Shopee E-Commerce Platform Likely in Reinvestment Phase -- Market Talk

2026. g. 3. apr. 01:44 UTC

Tirgus saruna

Samsung Likely to Report Record Quarterly Earnings in 2026 -- Market Talk

2026. g. 3. apr. 01:22 UTC

Tirgus saruna

Dollar Could Hit 160 Yen in Thin Holiday Trading -- Market Talk

Salīdzinājums

Cenas izmaiņa

Microbot Medical Inc Prognoze

Cenas mērķis

By TipRanks

212.5% augšup

Prognoze 12 mēnešiem

Vidējais 7.5 USD 212.5%

Augstākais 12 USD

Zemākais 5 USD

Pamatojoties uz 3 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Microbot Medical Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

3 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 3 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Microbot Medical Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

2.52 / 2.57Atbalsts un pretestība

The bullish and bearish events are balanced.

Recent bullish events outweigh bearish events.

All events are bullish.

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Microbot Medical Inc

Microbot Medical Inc., a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces. It also provides NovaCross, an intellectual property and technology in the field of intraluminal revascularization devices with anchoring mechanism and integrated microcatheter. The company has a strategic collaboration agreement with Stryker Corporation for technology co-development; and Phase 2 collaboration agreement with Corewell Health for the development of LIBERTY endovascular robotic system. Microbot Medical Inc. was founded in 2010 and is based in Braintree, Massachusetts.